Rationale and Design of the Türkiye Heart Failure (TURK‐HF) Registry

Figure 1. Geographical distribution of 22 cities in Türkiye that participated in the TURK‐HF registry.

Figure 2. Baseline and follow‐up data elements and time points for patients with chronic heart failure (outpatients) and acute heart failure (hospitalized patients). *Follow‐up data will be collected at regular outpatient visits every 6 months, with a margin of error of 1 month, or via telephone interviews if the patient is not eligible for outpatient visits. **The clinical endpoints of the TURK‐HF registry were cardiovascular or all‐cause mortality, heart failure‐related hospitalizations, clinician‐interpreted outcomes (e.g., New York Heart Association functional class), patient‐reported outcomes (e.g., health‐related quality of life), and surrogate endpoints (e.g., N‐terminal pro‐brain natriuretic peptide levels), either alone or in combination.

Figure 3. An example of the Turkish version of the EQ‐5D‐5L descriptive system integrated into the electronic case report form in the TURK‐HF registry (A), an example of the English version of the EQ‐5D‐5L descriptive system (B), and an example of THE EQ visual analog scale (C).

Figure 4. An example of the automatic calculation system integrated into the electronic case report form as a “decision support tool” to calculate the H2FPEF score in patients with heart failure with preserved ejection fraction.

Figure 5. “Treatment assessment algorithm” integrated into the electronic case report form to determine the use or non‐use of guideline‐directed medical therapies by registry participants. Step‐1: Determine the evidence‐based medication classes* (RAS inhibitors, β‐blockers, MRAs, and SGLT‐2 inhibitors) used by the registry participants. Step‐2: In instances where patients were not receiving treatment for HF, the patient and participant physician were asked to provide a rationale** (e.g., symptomatic hypotension for RAS inhibitors, bradycardia for β‐blockers, hyperkalemia for MRAs, or urinary tract infections for SGLT‐2 inhibitors). Step‐3: In instances where patients were receiving treatment for HF, determine the molecule that the participant used*** (e.g., ramipril for RAS inhibitors, bisoprolol for β‐blockers, eplerenone for MRAs, and dapagliflozin for SGTL‐2 inhibitors). Step‐4: Determine the daily dosage of medication that the participant used (e.g., ramipril 2.5 mg once daily, bisoprolol 10 mg once daily, eplerenone 25 mg once daily, and dapagliflozin 10 mg once daily). Step‐5: Determine whether the participant used the target dose of treatment or not# (< 50% of target dose, ≥ 50% to…

Figure 6. Data elements and time points for hospitalized patients with acute heart failure.